03/14/00 JC625 U.S. PTO

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
REQUEST FOR FILING APPLICATION UNDER 37 CFR 53(b)
WITHOUT FILING FEE OR EXECUTED INVENTOR'S DECLARATION

Assistant Commissioner for Patents
Washington, D.C. 20231

Atty. Dkt. 622-39
Date: **March 14, 2000**

Sir:

This is a request for filing a new PATENT APPLICATION under Rule 53(b) entitled:

PHARMACEUTICAL COMPOSITIONS BASED ON DICLOFENAE

without a filing fee and/or without an executed inventor's oath/declaration.
This application is made by the below identified inventor(s). Attached hereto are the following papers:

☒ An abstract together with
21 pages of specification and claims including
28 numbered claims and also attached is/are
7 sheets of accompanying drawings.
☒ This application is based on the following prior foreign application(s):

Application No.	Country	Filing Date
MI96A000992	**Italy**	**17 May 1996**
PCT/EP97/02709		**15 May 1997**

respectively, the entire content of which is hereby incorporated by reference in this application, and priority is hereby claimed therefrom.

☐ This application is based on the following prior provisional application(s):

Application No.	Filing Date

respectively, the entire content of which is hereby incorporated by reference in this application, and priority is hereby claimed therefrom.

☐ Certified copy/ies of foreign applications attached.
☒ This application is a ☐ continuation/☐ division/☒ continuation-in-part of application Serial No. 09/192,493, filed 17 November 1998.
☒ Please amend the specification by inserting before the first line: --This application is a ☐ continuation/☐ division/ ☒ continuation-in-part of application Serial No. 09/192,493, filed 17 November 1998, the entire content of which is hereby incorporated by reference in this application.--
☐ Please amend the specification by inserting before the first line: --This is a continuation of PCT application No. , filed , the entire content of which is hereby incorporated by reference in this application.--
☐ Please amend the specification by inserting before the first line: --This application claims the benefit of U.S. Provisional Application No. , filed , the entire content of which is hereby incorporated by reference in this application.--
☐ Preliminary amendment to claims (attached hereto), to be entered before calculation of the fee.
☐ Also attached.

1. Inventor: **Alberto** (first) MI **Reiner** (last) **Italian** (citizenship)
Residence: (city) **Como** (state/country) **Italy**
Post Office Address: **Via Mentana 23/D, I-22100, Como, Italy** (incl zip code)

2. Inventor: **Giorgio** (first) MI **Reiner** (last) **Italian** (citizenship)
Residence: (city) **Como** (state/country) **Italy**
Post Office Address: **Via Rusconi 24, I-22100, Como, Italy** (incl zip code)

NOTE: FOR ADDITIONAL INVENTORS, check box ☐ and attach sheet with same information.
Address all future communications to NIXON & VANDERHYE P.C., 1100 North Glebe Road, 8th Floor, Arlington, Virginia 22201.

1100 N. Glebe Road, 8th Floor
Arlington, Virginia 22201
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

NIXON & VANDERHYE P.C.
By Atty.: **Leonard C. Mitchard**, Reg. No. **29,009**

Signature: _____

LCM:lks

410426

Our Ref.: **622-39**
97 MG 19 E 14/CIP

U.S. PATENT APPLICATION

Inventor(s): Alberto Reiner
Giorgio Reiner

Invention: PHARMACEUTICAL COMPOSITIONS BASED ON DICLOFENAE

NIXON & VANDERHYE P.C.
ATTORNEYS AT LAW
1100 NORTH GLEBE ROAD
8TH FLOOR
ARLINGTON, VIRGINIA 22201-4714
(703) 816-4000
Facsimile (703) 816-4100

SPECIFICATION

Pharmaceutical compositions based on Diclofenac

The present invention relates to new immediate release pharmaceutical compositions containing [(2,6-dichloro-anilino)-2-phenyl]-2-acetic acid (more commonly known as Diclofenac) in acid and/or salt form.

Diclofenac is a non-steroidal drug which was invented at the end of the sixties by A.Sallmann and R.Pfister (NL-6,604,752 and US-3,558,690 both to Ciba-Geigy) and whose structural formula is indicated below.



Diclofenac is widely dispensed and used owing to its well-known analgesic, anti-pyretic, anti-arthritic, anti-phlogistic and anti-rheumatic properties and it is generally taken orally in the form of normal tablets or tablets covered with coatings resistant to gastric juices, or rectally, or by injection, or topically.

The possibility of taking it in the form of sweets, tablets dissolving in the mouth, drages, chewing gum or other similar pharmaceutical forms or in formulations for the extemporary preparation of Diclofenac-based aqueous solutions and/or suspensions would represent a different mode of administration which is definitely more suitable, especially for children and elderly persons.

Owing to its poor solubility in water, Diclofenac is normally used in salt form; the salts of Diclofenac customarily used are those of sodium, potassium or other alkali and alkaline earth metals, together with salts of organic nature, such as the salts of basic amino acids, such as lysine, arginine and ornithine, or other pharmacologically acceptable organic bases which have the ability to render the resulting salt soluble in water.

The pharmaceutical compositions of the Diclofenac salts for oral use are generally accompanied by side effects of not inconsiderable consequence: Diclofenac salts

are in fact characterised by a particularly unpleasant and bitter taste and by the fact that they produce a sensation of strong astringency and cause an especially intense form of irritation in the buccal cavity, especially in the area of the larynx.

Although the first problem has been partly solved by using flavourings which are able in some manner to mask the taste, satisfactory solutions have still not been proposed for the two remaining problems.

Therefore, the pharmaceutical compositions containing Diclofenac salts still have a poor palatability which limits their adoption and possible fields of application, despite the excellent therapeutic effect with which they are associated.

A second problem connected to Diclofenac is that, when it is orally administered by means of immediate release formulations, the corresponding T_{max} (the time to the maximum plasma concentration) is usually located at about 1 hour since administration, this being of course a not completely satisfactory result when a prompt and strong analgesic/anti-pyretic effect is sought for. Furthermore, the corresponding coefficient of variation is normally in the range of 70-90%, which means that the T_{max} is strongly variable and dependent on the physical characteristics of the patient (Physicians' Desk Reference, 52 edition, 1998, pag. 1831). Attempts are therefore still being made in order to enhance the rate of absorption of Diclofenac and to provide an earlier onset of the therapeutical effect (N. Davies, K. Anderson; Clinical Pharmacokinetic of Diclofenac, Clin.Pharmacokinet., 1997, Sept. 33(3).

The object of the present invention is therefore that of providing a fully palatable formulation of Diclofenac which is able to generate a more rapid, uniform and foreseeable release of the active principle if compared to the compositions known in the art and presently available on the market. For the purposes of the present invention T_{max} means the time to the maximum plasma concentration whereas C_{max} is the maximum plasma concentration of the active principle, namely Diclofenac.

It has now been found that, by adding alkali metal bicarbonates or mixtures thereof to the Diclofenac in its acid and/or salt form, in amounts of from 20 to 80

% by weight based on the acid-form of Diclofenac, pharmaceutical compositions can be obtained which are substantially free from the side effects mentioned above. The first object of the present invention is therefore represented by a pharmaceutical formulation for oral use containing Diclofenac in acid and/or salt form together with alkali metal bicarbonates or mixtures thereof and customary excipients and adjuvants, wherein said alkali metal bicarbonates are present in amounts of from 20 to 80 % by weight based on the weight of Diclofenac.

It has in fact been surprisingly demonstrated that the use of alkali metal bicarbonates in the above-mentioned ratio permits to achieve constant, reproducible and foreseeable blood levels of the active ingredient, with the consequent indisputable advantages from the therapeutic point of view; furthermore, it has also been found that the combined use of Diclofenac together with alkali metal bicarbonates yields Diclofenac-based pharmaceutical compositions in which the active ingredient is released more rapidly compared with normal formulations, bringing about higher blood levels and therefore a more immediate therapeutic effect; finally the so-obtained immediate release formulations are substantially palatable and free from aftertaste.

According to the preferred embodiment of the present invention, the amount of alkali metal bicarbonates to be added is comprised between 40 and 80% by weight, based on the weight of the acid-form Diclofenac, whereas the alkali metal bicarbonates are selected from sodium and/or potassium bicarbonates, Diclofenac being normally present in the form of its sodium and/or potassium salts.

It has also been found, and forms a second subject of the present invention, that the addition of flavouring substances selected from mint, aniseed, ammonium glycyrrhizinate and mixtures thereof to the compositions containing the Diclofenac salts and alkali metal bicarbonates produces a synergistic effect which completely eliminates all the above-mentioned palatability/astringency effects, providing pharmaceutical compositions which are entirely palatable (and/or drinkable in the

case of those used for the preparation of solutions and/or suspensions) and free from aftertaste.

The flavouring substances may be used as such or supported on inert materials, for example maltodextrin, in order to obtain a better distribution of the granulates and to facilitate excellent dispersibility of the flavouring in solution. Preferably, they are absorbed on maltodextrin with a power of 1 to 2000 and 1 to 1000.

The amount of flavouring substances in its pure form is also preferably from 1/5 to 3 times the weight of the acid-form Diclofenac.

These flavouring substances are used in the implementation of the present invention without altering their organoleptic properties and without depriving them of their intrinsic qualities of flavourings which are liposoluble and generally oily in the pure state.

As it will be clear from the examples, the immediate release formulations for oral use of the present invention containing from 10 to 60 mg of Diclofenac in acid and/or salt form together with alkali metal bicarbonates or mixtures thereof in amounts of from 20 to 80 % by weight based on the weight of Diclofenac permit to generate in human patients an average C_{max} of Diclofenac comprised between 400 and 2500 ng/ml independently on the age, sex or weight of the patients themselves.

Secondly, the formulations according to the present invention permit to obtain in humans an average T_{max} of Diclofenac after 5÷30 minutes since administration, generally 13÷27, independently on the amount of Diclofenac contained therein and also independently on the age, sex, weight of the patient.

Furthermore, the T_{max} of the formulations of the present invention show a coefficient of variation which is about 44-86% lower than the presently marketed formulations; this is evidently an extremely important result from the clinical point of view as it is now possible to have a therapeutical effect of Diclofenac which is foreseable, reproducible and independent on the sex, weight and health conditions of the patient.

Thus, the presently claimed Diclofenac-based formulations permit to achieve a higher C_{max} in a shorter T_{max} and with a lower corfficient of variation if compared to the formulations available on the market, with therapeutical advantages which do not need to be commented.

According to the best mode for carrying out the present invention the pharmaceutical formulations will contain from 10 to 60 mg/dose of diclofenac in its potassium or sodium salt form together with 40 to 80% by weight of potassium or sodium bicarbonate based on the weight of Diclofenac in its acid form, together with the usual excipients and adjuvants; even more preferably they will packaged as:

- a sachet or tablet formulation containing 50 mg of Diclofenac potassium salt and 22 mg of potassium bicarbonate or 50 mg of Diclofenac sodium salt and 19 mg of sodium bicarbonate;
- a sachet or tablet formulation containing 12.5 mg of Diclofenac sodium salt and 5.5 mg of potassium bicarbonate or 25 mg of Diclofenac sodium salt and 11 mg potassium bicarbonate.

It will be by the way evident to any skilled in this art that the present formulations can also be used as immediate release layers of multilayered release pharmaceutical formulations containing Diclofenac as one of the active ingredients; said formulations are therefore a further object of the present invention.

The following Examples are given purely by way of non-limiting illustration.

Example 1 - Composition dissolving instantly in water

- Active ingredients

1) Diclofenac potassium salt* :	50 mg
2) Potassium bicarbonate:	22 mg
3) Mint flavouring on maltodextrin(1:2000)**:	60 mg
4) Aniseed flavouring on maltodextrin (1:1000)***:	104 mg

- Excipients and adjuvants

5) Saccharin:	4 mg
6) Aspartame:	10 mg
7) Mannitol:	50 mg
8) Saccharose*** *q.s.:	2 g

* If it is desired to prepare compositions based on Diclofenac sodium salt, it is advantageous to use sodium bicarbonate in a quantity of approximately 38% by weight based on the weight of the Diclofenac sodium salt present.

Sodium carbonate may also be added to the sodium bicarbonate, maintaining the following optimum proportions: 27 % of sodium bicarbonate and 4-5 % of sodium carbonate, always based on the amount by weight of Diclofenac sodium salt present.

** The title of the pure mint essence, as obtained according to the Dean-Stark method, is of 18% by weight; the related amount is therefore in this case of 10.8 mg.

*** The title of the pure anise essence, as obtained according to the Dean-Stark method, is of 14.5% by weight, the related amount is therefore in this case of 16 mg.

**** The presence of saccharose is not strictly necessary; in its absence, a composition having a very limited granulate content is obtained which is perfectly soluble in contact with water. In that case, nothing is changed from the point of view of tolerability in contact with the mucosa and from the point of view of the palatability of the drinkable solution.

- Preparation

Components 1, 2, 5, 6 and 7 are mixed in a suitable mixer, and the mixture so obtained is wetted with 95% ethanol. Granulation is carried out with a 66 mm mesh and the granulate is preferably dried in a current of air.

Components 3, 4 and 8, which have already been granulated using a mesh of the same granulometry, are then added and the whole is mixed.

The mixture is then introduced into a metering machine filling packets or similar

containers.

Example 2 - Tablet for dissolving in the mouth

- Active ingredients	
1) Diclofenac potassium salt*:	50 mg
2) Potassium bicarbonate:	35 mg
3) Mint flavouring on maltodextrin** (1:2000) + gum arabic (E 414):	50 mg
4) Aniseed flavouring (1:1000) on maltodextrin*** + silicon dioxide (E 551):	120 mg
- Excipients and adjuvants	
5) Saccharin:	50 mg
6) Aspartame:	12 mg
7) Mannitol:	20 mg
8) Saccharose****:	300 mg

* to**** see Example 1

Example 3 - Gum tablet

- Active ingredients	
1) Diclofenac potassium salt*:	50 mg
2) Potassium bicarbonate:	35 mg
3) Mint flavouring on maltodextrin**:	30 mg
4) Aniseed flavouring on maltodextrin***:	80 mg
- Excipients and adjuvants	
5) Mannitol:	30 mg
6) Menthol:	0.01 mg
7) Gum base:	600 mg
8) Sorbitol:	700 mg
9) Saccharin:	3 mg

10) Hydroxypropylmethylcellulose: 33 mg

11) Colouring agent: 7 mg

* to*** see Example 1

Example 4 - Comparative test

The packaged composition containing 50 mg of Diclofenac potassium of Example 1 (formulation C) was subjected to a pharmacokinetic test for comparison with a similar composition not containing alkali metal carbonates and bicarbonates (formulation B), and with a second composition in tablet form (formulation A) produced by Ciba-Geigy (Voltaren Rapid ®), also in this case not containing alkali metal carbonates and bicarbonates, both formulations A and B containing 50 mg of Diclofenac potassium.

This comparative evaluation was carried out on the same 6 healthy volunteers in accordance with the experimental plan described hereinafter.

- Experimental scheme: Single-dose study using three methods in randomised cross- over with a wash-out of three days.
- Sampling times: 0h (before administration), 5 min, 10 min, 30 min, 45 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, after each administration.
- Blood sample treatment: 8MI in heparinised test tubes, centrifugation for 15 min at 1500 rev/min, subdivided into two fractions and subsequently frozen at -20°C.
- Times: wash-out of two days between treatments.
- Determination method: HPLC, with internal standard, sensitivity 10 ng/ml.

Analysis method

- Column: Nova Pak C18, 3.9x150 mm, 4 µm Waters S.p.A. - Vimodrone, Italy.
- Eluant: NaH2PO4 0.01 M + 0.1 % TEA, pH 3.0 (H3PO4)/acetonitrile, 60/40.
- Flow: 1.2 ml/min
- Detection: UV/275 nm
- Temperature: 30°C
- Injection: 50 al
- Analysis time: 16 min.

Sample preparation

10 al of the internal standard methanolic solution, and flufenamic acid (corresponding to

1320 ng) are added to 1 ml of defrosted plasma in 10 ml glass test tubes. The tubes are agitated in a Vortex mixer for 1 minute. 0.5 ml of a 0.5N HCl/1N NaCl solution is added. The whole is agitated in a Vortex mixer for 1 minute. 6 ml of a 95/5 n-hexane/isopropanol solution are added.

The mixture is then agitated in the Vortex mixer for a further 15 minutes. Centrifugation is carried out at 3000 rev/min for 15 minutes and the organic phase is transferred to fresh 10 ml glass test tubes and evaporated to dryness in a centrifugal evaporator under vacuum at ambient temperature. The whole is taken up in 200 al of a 70/30 acetonitrile/water solution, and the precipitate is dissolved under ultrasound for 2 minutes.

Figures 1, 2 and 3 show the concentrations of Diclofenac in the blood of the six volunteers as regards formulations A, B (Ciba-Geigy comparative formulations) and C (formulation corresponding to the composition of Example 1), respectively. As will be appreciated, the blood concentration of the formulation of the present invention has, compared with the comparative formulations, a more constant and uniform pattern. This characteristic is also found in Figures 4, 5 and 6 which show the average values corresponding to the blood levels of the six volunteers together with the corresponding standard deviation.

The result is clear and surprising: compared with the sample compositions, the compositions of the present invention permit constant, reproducible and foreseeable blood levels of the active ingredient, irrespective of the characteristics of the volunteer (weight, age, etc), with the consequent indisputable advantages from the therapeutic point of view.

Finally, Figure 7 shows, by comparison, the graphs relating to the average values of the six volunteers (that is to say, the preceding Figures 4, 5 and 6); as will be noted, the formulation of the present invention permits, in addition to the

advantages already mentioned, the attainment of a blood peak higher than that of the other formulations.

Example 5 - Two layered tablet (fast and slow release)

Fast release layer

1) Diclofenac potassium salt:	15 mg
2) Potassium bicarbonate:	30 mg
3) Lactose:	13.2 mg
4) Maize starch (intragranular):	6 mg
5) Methyl cellulose:	0.12 mg
6) Sodium laurylsulfate:	0.06 mg
7) Maize starch (extragranular):	9 mg
8) Crospovidone:	0.6 mg
9) Sodium carboxtmethylstarch:	1.5 mg
10) Magnesium stearate:	2.7 mg
11) Colloidal silicon dioxide:	0.6 mg

Slow release layer

1) Diclofenac potassium salt:	70 mg
2) Potassium bicarbonate:	30.8 mg
3) Lactose:	32.2 mg
4) Polyvinylpyrrolidone:	1.16 mg
5) Hydrpxypropylmethylcellulose:	70 mg
6) Magnesium stearate:	0.84 mg
7) Colloidal silicon dioxide:	0.21 mg
8) Talc:	3.92 mg
9) Polyethylene glycol:	0.56 mg

Example 6 - Drops

1) Diclofenac potassium salt:	75 g
2) Methyl p-oxybenzoate:	2.7 g
3) Propyl p-oxybenzoate:	0.3 g

4) Aspartame: 37.5 g

5) Potassium bicarbonate: 37.5 g

6) Glycerol: 300 g

7) Ethyl alcool: 450 g

8) Water q.s.: 1500 g

Possible modifications:

a) Addition of sodium metabisulfite (0.06%)

b) Addition of sodium metabisulfite (0.06%)

Mint flavouring (1.25%)

Strawberry flavouring (0.75%)

Example 7 - Drops

1) Diclofenac potassium salt: 37.5 g

2) Methyl p-oxybenzoate: 2.7 g

3) Propyl p-oxybenzoate: 0.3 g

4) Aspartame: 37.5 g

5) Potassium bicarbonate: 18.75 g

6) Saccharin: 6.0 g

7) Glycerol: 300 g

8) Ethyl alcool: 450 g

9) Water q.s.: 1500 g

Possible modifications:

a) Addition of sodium metabisulfite (0.03%)

b) Addition of sodium metabisulfite (0.03%)

Mint flavouring (1.25%)

Strawberry flavouring (0.75%)

Example 8 - Mouthwash

1) Diclofenac potassium salt: 0.75 g

2) Glycerol: 50 g

3) Sorbitol: 12 g

4) Saccharin:	0.5 g
5) Aspartame:	1.0 g
6) Methyl p-oxybenzoate:	0.5 g
7) Propyl p-oxybenzoate:	0.1 g
8) Mint flavouring:	1.0 g
9) Ethyl alcool:	100 g
10) Potassium bicarbonate:	0.33 g
11) Water q.s.:	500 ml

Example 9 - Gum-paste

1) Diclofenac potassium salt:	5.0 g
2) Glycerol:	630 g
3) Sodium benzoate:	5.0 g
4) Silica (Wessalon S® - Degussa):	120 g
5) Silica (Siddent 9® - Degussa):	80 g
6) Cellulose gum:	3.0 g
7) Polyethylenglycol 600:	30 g
8) Sodium lauroyl sarcosinate (or sodium lauryl sulfate):	60 g
9) Mint flavouring:	10 g
10) Sodium saccharin:	1.0 g
11) Aspartame:	3.0 g
12) Potassium bicarbonate:	2.2 g
13) Water q.s.:	1 kg

Example 10 - Tooth-paste

1) Diclofenac potassium salt:	5.0 g
2) Glycerol:	630 g
3) Sodium benzoate:	5.0 g
4) Silica (Wessalon S® - Degussa):	20 g
5) Silica (Siddent 9® - Degussa):	80 g
6) Cellulose gum:	3.0 g

7) Polyethylenglycol 600:	30 g
8) Sodium lauroyl sarcosinate (or sodium lauryl sulfate):	60 g
9) Mint flavouring:	10 g
10) Sodium saccharin:	1.0 g
11) Aspartame:	3.0 g
12) NaF:	1.0 g
13) Na_2FPO_3:	4.0 g
14) Potassium bicarbonate:	2.2 g
15) Water q.s.:	1 kg

Example 11 - Tablet

1) Diclofenac potassium salt:	50 mg
2) Mannitol:	50 mg
3) Potassium bicarbonate:	22 mg
4) Maize starch (intragranular):	10 mg
5) Methyl cellulose:	0.2 mg
6) Sodium laurylsulfate:	0.1 mg
7) Maize starch (extragranular):	15 mg
8) Crospovidone:	1.0 mg
9) Sodium carboxymethylstarch:	2.5 mg
10) Magnesium stearate:	4.5 mg
11) Colloidal silicon dioxide:	10 mg

Example 12 – comparative test

In the present experiment a sachet formulation containing 50 mg of Diclofenac potassium was compared to a bioequivalent sugar coated fast release tablet also containing 50 mg of Diclofenac potassium, produced and marketed in Italy by Novartis as Cataflam®.

The sachet formulation according to the present invention had the following composition:

1) Diclofenac potassium salt:		50 mg
2) Potassium bicarbonate:		22 mg
3) Mint flavour:	:	50 mg
4) Anice flavour	:	100 mg
5) Saccharin sodium:		4 mg
6) Aspartame:		10 mg
7) Mannitol:		50 mg
8) Sucrose sugar crystals:		1714 g

The above test formulation and the Cataflam® formulation were administered as a single dose to 24 healty volunteers of both sexes. The pharmacokinetic parameters obtained with the two different formulations are reported in table 1 and in figure 5. As it will be easily appreciated, the rate of absorption was considerably faster with the sachet formulation of the present invention than with Cataflam®, the sachet formulation having a higher average C_{max} (2213 vs 1071 ng/ml) and a shorter average T_{max} (0.228 vs 0.885 hours); furthermore, the T_{max} of the sachet formulation shows a coefficient of variation lower than the reference formulation (16% vs 97%), this being an extremely important result from the clinical point of view regarding the healing of the pain in terms of quick time and repeteability inter-subjects in order to reach the C_{max}.

Example 13 – comparative test

Following to the excellent results obtained in example 12, two tablet formulations containing 12.5 or 25 mg of Diclofenac sodium salt and potassium bicarbonate (in the same weight ratio) have been prepared.

The tablet formulations had the following composition (in mg):

Cores

Diclofenac sodium	12.5	25
Mannitol	25	50

Lactose monohydrate	23.75	47.5
Potassium bicarbonate	5.5	11
Maize starch	22.5	45
Methylcellulose	0.075	0.15
Sodium laurylsulphate	0.125	0.25
Crospovidone	3	6
Ultramyl	5	10
Coloidal silica	0.55	1.1
Cellulose microcrystalline	0.5	1
Magnesium stearate	1.5	3
Purified water q.s.	100	200
Coating		
Opadry OY-35009 red	2	4
Macrogol 400	0.25	0.5

A four-way comparative bioavailability study was carried out on 18 healty volunteers of both sexes in order to evaluate the in vivo results of the pharmaokinetic profiles of the present formulations if compared to those of bioequivalent fast release formulations such as Cataflam® (25 mg of Diclofenac potassium) and Voltarol® (50 mg of Diclofenac sodium), both by Novartis. The results, which are summarized in figure 6, indicate that T_{max} is prompter with the present formulations (T1 = 26 min, T2 = 24.6 min vs R1 = 71.4 min and R2 = 40.8 min) and that C_{max} is higher (T1 = 847 ng/ml and T2 = 861 ng/ml vs R1 = 452 ng/ml and R2 = 703 ng/ml); furthermore, the T_{max} of both present formulations shows a coefficient of variation lower than reference formulations (T1 = 46% and T2 = 49% vs R1 = 87% and R2 = 96%).

Example 14 – comparative test

A further comparative test was carried out on immediate release formulations according to the present invention, containing 50 mg of Diclofenac potassium and 22 mg of potassium bicarbonate, manufactured with different that is, respectively: T1 = wet granulation using alcohol, T2 = dry granulation by direct compression. The composition in mg of the two formulations is herebelow reported:

Diclofenac potassium	50	50
Potassium bicarbonate	22	22
Mannitol/pearlitol 400 DC	119.9	
Mannitol EP cf		50
Maize starch		25
Methocel A4C		0.2
Sodium laurylsulphate	0.1	0.1
Polyplasdone XL	6	1
Ultramyl		2.5
Magnesium stearate	2	4.5
Silicium aerosil		1
Core mass	200	156.3

A comparative bioavailability study was carried out on 6 healty volunteers of both sexes in order to evaluate the in vivo results of the pharmaokinetic profiles of the present formulations if compared to those of a bioequivalent fast release formulation such Voltarene Rapid® (50 mg of Diclofenac potassium), both by Novartis. The results, which are reported in figures 7-10 are also in this case excellent: the T_{max} is in fact prompter with the present formulations (T1 = 18.6 min, T2 = 16.8 min vs R1 = 40.8 min) and the C_{max} is higher (T1 = 1878.3 ng/ml and T2 = 1744.8 ng/ml vs R1 = 1307 ng/ml); furthermore, also in this case the T_{max} of both present formulations shows a coefficient of variation lower than reference formulation (T1 = 12.9% and T2 = 25% vs R1 = 95.6%).

CLAIMS

1. An immediate release pharmaceutical formulation for oral use containing Diclofenac in acid and/or salt form together with alkali metal bicarbonates or mixtures thereof and customary excipients and adjuvants, wherein said alkali metal bicarbonates are present in amounts of from 20 to 80 % by weight based on the weight of Diclofenac.

2. A formulation according to claim 1 wherein said alkali metal bicarbonates are present in amounts of from 40 to 80 % by weight based on the weight of Diclofenac.

3. A formulation according to claim 1 characterized in that Diclofenac is present in its potassium and/or sodium salt form.

4. A formulation according to claim 3 wherein said alkali metal bicarbonates are potassium and/or sodium bicarbonates.

5. A formulation according to claim 3 which contains from 10 to 60 mg of Diclofenac sodium and/or Diclofenac potassium.

6. A formulation according to claim 1 which contains at least one flavouring substance selected from mint, aniseed and ammonium glycyrrhizinate.

7. A formulation according to claim 6 wherein said at least one flavouring substance is present in pure form in an amount of from 1/5 to 3 times by weight based on the weight of Diclofenac.

8. A pharmaceutical formulation for oral use comprising at least an immediate release layer and at least a delayed release layer, said immediate release layer containing Diclofenac in acid and/or salt form together with alkali metal bicarbonates or mixtures thereof and customary excipients and adjuvants, wherein said alkali metal bicarbonates are present in amounts of from 20 to 80 % by weight based on the weight of Diclofenac.

9. A pharmaceutical formulation according to claim 8 wherein said second delayed release layer also contains Diclofenac as the active principle.

10. A formulation according to claim 8 wherein said alkali metal bicarbonates are present in amounts of from 40 to 80 % by weight based on the weight of Diclofenac.

11. A formulation according to claim 8 characterized in that Diclofenac is present in its potassium and/or sodium salt form.

12. A formulation according to claim 11 wherein said alkali metal bicarbonates are potassium and/or sodium bicarbonates.

13. A method for generating an average C_{max} of Diclofenac comprised between 400 and 2500 ng/ml in human patients in need of such a treatment, which comprises administering to those patients a pharmaceutical formulation containing from 10 to 60 mg of Diclofenac in acid and/or salt form together with alkali metal bicarbonates or mixtures thereof and customary excipients and adjuvants, wherein said alkali metal bicarbonates are present in amounts of from 20 to 80 % by weight based on the weight of Diclofenac.

14. A method according to claim 13 wherein said alkali metal bicarbonates are present in amounts of from 40 to 80 % by weight based on the weight of Diclofenac.

15. A method according to claim 14 wherein said alkali metal bicarbonates are sodium and/or potassium bicarbonates.

16. A method according to claim 14 wherein said average Cmax of Diclofenac is comprised between 1700 and 2300 ng/ml and said pharmaceutical formulation contains about 50 mg of Diclofenac in its potassium and/or sodium salt form.

17. A method according to claim 14 wherein said average Cmax of Diclofenac is comprised between 800 and 900 ng/ml and said pharmaceutical formulation contains about 25 mg of Diclofenac in its potassium and/or sodium salt form.

18. A method according to claim 14 wherein said average Cmax of Diclofenac is comprised between 400 and 500 ng/ml and said pharmaceutical formulation contains about 12.5 mg of Diclofenac in its potassium and/or sodium salt form.

19. A method according to claim 13 wherein said average Cmax of Diclofenac is reached after 13÷27 minutes since administration.

20. A method for obtaining an average T_{max} of Diclofenac after 5÷30 minutes since administration in human patients in need of such a treatment, which comprises administering to those patients a pharmaceutical formulation containing Diclofenac in acid and/or salt form together with alkali metal bicarbonates or mixtures thereof and customary excipients and adjuvants, wherein said alkali metal bicarbonates are present in amounts of from 20 to 80 % by weight based on the weight of Diclofenac.

21. A method according to claim 20 wherein said T_{max} of Diclofenac is reached after 13÷27 minutes since administration.

22. A method according to claim 20 wherein said pharmaceutical formulation contains from 10 to 60 mg of Diclofenac in acid and/or salt form.

23. A method according to claim 22 wherein said alkali metal bicarbonates are present in amounts of from 40 to 80 % by weight based on the weight of Diclofenac.

24. A method according to claim 23 wherein said alkali metal bicarbonates are sodium and/or potassium bicarbonates.

25. A method according to claim 20 wherein said formulation is a pharmaceutical formulation for oral use comprising at least an immediate release layer and at least a delayed release layer, said immediate release layer containing Diclofenac in acid and/or salt form together with alkali metal bicarbonates or mixtures thereof and customary excipients and adjuvants, wherein said alkali metal bicarbonates are present in amounts of from 20 to 80 % by weight based on the weight of Diclofenac.

26. A method according to claim 25 wherein said second delayed release layer also contains Diclofenac as the active principle.

27. A method according to claim 25 wherein said alkali metal bicarbonates are present in amounts of from 40 to 80 % by weight based on the weight of Diclofenac.

28. A method according to claim 27 characterized in that Diclofenac is present in its potassium and/or sodium salt form and said alkali metal bicarbonates are potassium and/or sodium bicarbonates.

TABLE 1

Pharmacokinetic parameters for two different diclofenac formulations: test (Diclofenac potassium salt sachets) and reference (Diclofenac potassium salt sugar coated tablets)

	t_{max} (h)		C_{max} (ng/mL)		$t_{½}$ (h)		AUC_{0-t} (ng•mL^{-1}•h)		$AUC_{0-\infty}$ (ng•mL^{-1}•h)		C_t		$C_{max}/AUC_{0-\infty}$ (h^{-1})		AUC extrapolated (%)	
Vol. no.	Test	Ref.	Test	Ref.	Test	Ref.	Test	Ref.	Test	Ref.	Test	Ref.	Test	Ref.	Test	Ref.
Vol. 1	0.250	0.500	1573.000	1186.211	1.505	0.939	1024.511	885.549	1050.137	910.868	11.800	18.700	1.498	1.302	2.37	0.00
Vol. 2	0.250	4.000	2382.368	965.100	0.875	1.358	1653.124	2092.036	1693.172	2092.036	31.700	13.500	1.407	0.461	1.82	1.38
Vol. 3	0.184	1.000	2614.655	1352.400	0.796	1.610	1687.529	1763.484	1718.755	1788.111	27.200	10.600	1.521	0.756	0.83	1.15
Vol. 4	0.250	3.000	2404.848	735.454	0.996	1.132	1881.944	1834.958	1897.754	1856.346	11.000	13.100	1.267	0.396	1.39	1.88
Vol. 5	0.250	0.500	2971.457	1405.000	1.667	1.903	1819.756	1687.075	1845.486	1719.478	10.700	11.800	1.610	0.817	1.56	1.90
Vol. 6	0.250	0.750	2158.700	1351.500	0.843	0.650	1197.716	1091.996	1216.693	1113.146	15.600	22.500	1.774	1.214	2.50	1.79
Vol. 7	0.250	0.750	1739.200	1741.717	0.596	0.658	1448.713	1301.887	1485.867	1325.661	43.200	25.000	1.170	1.314	1.46	1.78
Vol. 8	0.250	0.500	1715.350	534.300	0.818	1.111	991.864	1126.414	1006.522	1146.775	12.400	12.700	1.704	0.466	3.08	2.75
Vol. 9	0.250	0.750	444.112	747.800	0.787	1.188	669.084	886.300	690.354	911.329	18.700	14.600	0.643	0.821	1.74	1.80
Vol. 10	0.267	0.750	2350.100	1110.400	0.960	1.070	1327.808	1020.286	1351.357	1038.971	17.000	12.100	1.739	1.069	3.01	3.01
Vol. 11	0.167	0.500	1867.200	1465.502	1.141	0.762	1337.821	892.870	1379.311	920.579	25.200	25.200	1.354	1.592	1.62	2.03
Vol. 12	0.167	0.500	4273.026	1432.200	1.052	0.697	1703.655	1139.003	1731.709	1162.638	18.500	23.500	2.468	1.232	1.26	1.56
Vol. 13	0.250	0.500	2097.089	1155.371	1.313	1.198	1486.526	1233.531	1505.454	1253.088	10.000	11.300	1.393	0.922	2.58	2.26
Vol. 14	0.167	0.250	2242.684	967.795	0.997	0.837	987.522	927.726	1013.665	949.163	18.200	17.700	2.212	1.020	1.91	2.86
Vol. 15	0.184	0.500	2040.247	1129.957	0.724	0.804	1213.725	1040.424	1237.399	1071.029	22.700	26.400	1.649	1.055	1.33	1.58
Vol. 16	0.250	0.750	2143.692	818.200	0.560	1.199	1186.603	1250.221	1202.653	1270.280	19.900	11.600	1.782	0.644	4.16	2.80
Vol. 17	0.250	1.500	1527.845	480.900	2.752	1.309	958.821	978.797	1000.433	1006.986	10.500	14.900	1.527	0.478	5.51	2.26
Vol. 18	0.250	1.000	1859.608	666.500	1.630	1.383	1131.413	933.008	1197.411	954.597	28.100	10.800	1.553	0.698	2.57	2.11
Vol. 19	0.250	0.750	1537.508	770.100	1.726	1.137	980.348	906.275	1006.229	925.835	10.400	11.900	1.528	0.832	2.03	2.02
Vol. 20	0.250	0.250	1956.004	655.100	0.853	0.883	1309.289	1036.836	1336.472	1058.242	22.400	16.800	1.464	0.619	1.19	1.07
Vol. 21	0.250	0.500	3551.360	2421.060	1.322	1.233	2147.217	1639.619	2173.030	1657.372	13.500	10.000	1.634	1.461	1.75	1.68
Vol. 22	0.167	0.500	2464.978	1274.648	0.611	0.624	1038.817	816.924	1057.293	830.908	21.000	15.500	2.331	1.534	3.13	1.80
Vol. 23	0.167	0.750	2304.351	453.500	2.066	0.862	1161.414	1049.327	1198.950	1068.588	12.600	15.500	1.922	0.424	2.19	1.94
Vol. 24	0.250	0.500	2901.504	894.337	0.970	1.279	1645.384	1086.512	1682.290	1108.024	26.400	11.700	1.725	0.807	2.10	1.78
Mean	0.228	0.885	2213.370	1071.461	1.148	1.076	1332.942	1192.544	1361.600	1214.169	19.113	15.725	1.620	0.914	2.213	1.883
SD	0.037	0.860	743.099	450.780	0.523	0.320	358.048	350.116	358.359	348.108	8.244	5.160	0.377	0.365	1.035	0.641
CV%	16.300	97.091	33.573	42.072	45.557	29.700	26.862	29.359	26.319	28.671	43.134	32.812	23.277	39.991	46.795	34.056
Min.	0.167	0.250	444.112	453.500	0.560	0.624	669.084	816.924	690.354	830.908	10.000	10.000	0.643	0.396	0.833	0.000
Max.	0.267	4.000	4273.026	2421.060	2.752	1.903	2147.217	2092.036	2173.030	2092.036	43.200	26.400	2.468	1.592	5.512	3.010
Geom. Mean	0.225	0.692	2070.719	987.180	1.056	1.032	1287.195	1150.713	1316.580	1173.325	17.609	15.011	1.573	0.841	2.023	//
Median	0.250	0.625	2151.196	1039.098	0.983	1.122	1261.507	1067.920	1286.936	1089.527	18.350	14.050	1.582	0.827	1.974	1.843

Title

Pharmaceutical compositions based on Diclofenac

Abstract

New pharmaceutical compositions for oral use containing Diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to Diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other side effects; in particular, these formulations permit to obtain in human patients higher C_{max} of the active principle and shorter T_{max} together with a lower coefficient of variation.

FIG. 1



FIG. 2

POTASSIUM DICLOFENAC

Formulation B - Average Value of the 6 volunteers



FIG. 3



FIG. 4


POTASSIUM DICLOFENAC
Formulation A - B - C - Average Value of the 6 volunteers
µg/ml
4000
3500
3000
2500
2000
1500
1000
500
0
0
20
40
60
80
100
120
140
160
180
200
220
240
time (min)
Form. A
Form. B
Form. C

FIG. 5

Mean, overlaid plasma concentration-time curves measured in all volunteers after administration of diclofenac test and reference formulations in linear and log-scale. Dose administered = 50 mg.



FIG. 6

Mean, overlaid plasma concentration-time profiles measured in all volunteers after administration of diclofenac T_1, T_2, R_1 (CATAFLAM®) and R_2 (VOLTAROL®) formulations; linear and log scales.



FIGURE 7

Mean plasma concentration-time profile of diclofenac measured in all volunteers after oral administration of T_1 formulation. Linear scale. Vertical bars are SD.



FIGURE 8

Mean plasma concentration-time profile of diclofenac measured in all volunteers after oral administration of T_2 formulation. Linear scale. Vertical bars are SD.



FIGURE 9

Mean plasma concentration-time profile of diclofenac measured in all volunteers after oral administration of R (VOLTARENE® RAPIDE) formulation. Linear scale. Vertical bars are SD.



FIGURE 10

Mean, overlaid plasma concentration-time profile of diclofenac measured in all volunteers after oral administration of T_1, T_2 and R (VOLTARENE® RAPIDE) formulation. Linear and log scales.